Prolium Bioscience
Prolium Bioscience is a clinical-stage biotechnology company developing PRO-203, a novel therapeutic candidate for severe autoimmune diseases. The company is currently evaluating PRO-203 in a multinational Phase 1/2 study for systemic sclerosis and an investigator-led study for refractory lupus nephritis, with the first patient dosed in the systemic sclerosis trial and the last patient visit completed in the lupus nephritis study.
- Drug Discovery & Therapeutics
- Biotechnology
- Healthcare Technology
Funding
Founders
Founder details are not available yet.
Product
Problem
Patients with severe autoimmune diseases such as systemic sclerosis and refractory lupus nephritis face limited treatment options and often experience inadequate responses to existing therapies. These conditions can lead to significant organ damage, disability, and reduced quality of life, yet current standard-of-care treatments frequently fail to achieve durable disease control.
Solution
Prolium Bioscience is a clinical-stage biotechnology company developing PRO-203, a novel therapeutic candidate targeting severe autoimmune conditions. The company is evaluating PRO-203 in a multinational Phase 1/2 study for systemic sclerosis and an investigator-led study for refractory lupus nephritis. With the first patient dosed in the systemic sclerosis trial and the last patient visit completed in the lupus nephritis study, PRO-203 is advancing through clinical development with the goal of providing a new treatment option for patients with high unmet medical need.
Target Audience
Patients with severe autoimmune diseases, specifically those with systemic sclerosis or refractory lupus nephritis, who have not adequately responded to existing therapies, along with the physicians and clinical trial sites that treat them.
Features
- Lead candidate PRO-203 currently in clinical-stage development for systemic sclerosis and refractory lupus nephritis
- Multinational Phase 1/2 study design for systemic sclerosis, allowing broad patient recruitment across geographic regions
- Investigator-led trial structure for refractory lupus nephritis, leveraging academic and clinical expertise
- Clinical development progress demonstrated by first patient dosed in the systemic sclerosis study and completion of the last patient visit in the lupus nephritis study